AF
RNAC icon

Allworth Financial’s Cartesian Therapeutics RNAC Stock Holding History

Allworth Financial’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$775 Buy
+126
New +$898 ﹤0.01% 4639
2025
Q3 		– Sell
-15
Closed -$156 – 5024
2025
Q2 		$156 Buy
+15
New +$160 ﹤0.01% 4348

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allworth Financial's RNAC Position: Q1 2026 in Review

Allworth Financial opened a new position in Cartesian Therapeutics (RNAC) in Q1 2026: 126 shares worth $775. The stake represents ﹤0.01% of the portfolio and ranks #4639 among its holdings. This is a return to the name: Allworth Financial previously reported a position in RNAC as recently as Q2 2025.

Allworth Financial first reported a position in RNAC in Q2 2025 and has held it in 2 quarters since. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Allworth Financial held 126 shares of Cartesian Therapeutics worth $775 as of Q1 2026.
  • Cartesian Therapeutics was a new Allworth Financial position in Q1 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4639 holding.
  • Allworth Financial first reported a position in Cartesian Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.